Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Anand Patel_2023
VIEWPOINTS

Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

Shots: Anand briefed PharmaShots about the study design and the results from the RELIEF-DPN-1 trial of its investigational drug LX9211 presented at the 16th Annual Pain Therapeutics Summit He spoke about how LX9211 met its primary endpoints and how the drug shows considerable promise as a novel therapeutic medication for the treatment of painful diabetic…
June 19, 2023

Read more

VIEWPOINTS_Philippe Halfon_2023
VIEWPOINTS

Philippe Halfon, President & Founder of Genoscience Pharma Shares Insights from the P-IIb Trial of Ezurpimtrostat to Treat Hepatocarcinoma

Shots: Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent) He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC alone The interview gives an…
June 15, 2023

Read more

VIEWPOINTS_Sheri Lewis1_Dr. Ger Brophy2_2023
VIEWPOINTS

Sheri Lewis and Dr. Ger Brophy of Avantor Share Insights on the Opening of a New Distribution Centre

Shots: Sheri talked about the opening of the new distribution center in Dublin, Ireland. The opening of the center highlighted Avantor’s continued investment to expand its global footprint strengthening its ability to provide essential products and services to the markets Dr. Ger Brophy spoke about the key benefits of the center to global biopharma customers.…
June 12, 2023

Read more

VIEWPOINTS_Avery Ince_2023
VIEWPOINTS

Avery Ince, VP, Medical Affairs – CVM Franchise, Janssen Shares his Views on New Data from P-III VOYAGER PAD Trial

Shots: Avery spoke about the study design and the new data obtained from the P-III VOYAGER PAD trial evaluating Xarelto + Aspirin to treat peripheral artery disease presented at the 72nd ACC 2023 The data demonstrated that the treatment with the Xarelto vascular dose following LER had a 33% reduction in acute limb ischemia and a 15%…
June 5, 2023

Read more

VIEWPOINTS_Anas Batikhi_2023
VIEWPOINTS

Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

Shots: Anas spoke about revenue cycle management in the healthcare sector and the traditional challenges in the healthcare RCM He also elaborated on how the evolving technologies can help to overcome the challenges in healthcare revenue cycle management The interview shows how Santechture is developing smart AI-based and cloud-based solutions to help healthcare providers develop…
June 2, 2023

Read more

VIEWPOINTS_Gregory Bell_2023
VIEWPOINTS

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Shots: Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease He also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…
May 30, 2023

Read more

VIEWPOINTS_David Pendlebury_2023
VIEWPOINTS

David Pendlebury, Head of Research Analysis, Institute for Scientific Information Shares Insights from its Annual Highly Cited Researchers List

Shots: David first talked about Clarivate’s Highly Cited Researchers 2022 list. He said that the list picks out 6,938 individuals at universities, research institutes, and commercial organizations across 69 countries/regions He also elucidated the methodology used by Clarivate to create the list and how the pharma companies can benefit from this list to strengthen their…
May 29, 2023

Read more

VIEWPOINTS_Dr. Samiah Al-Zaidy_2023
VIEWPOINTS

Dr. Samiah Al-Zaidy, VP of Clinical Development at Passage Bio Shares Insights on Additional Interim Data from the Imagine-1 Study for GM1 Gangliosidosis

Shots: Samiah Al-Zaidy spoke about the interim clinical data from Imagine-1, P-I/II trial of PBGM01 for GM1 gangliosidosis presented at the 19th Annual WORLDSymposium 2023 She also talked about how the presentation at WORLDSymposium contributed to raising awareness about GM1 Gangliosidosis which is a rare and fatal disease The interview showcases Passage Bio’s mission to…
May 22, 2023

Read more

VIEWPOINTS_Dr. Harmony Garges_2023
VIEWPOINTS

Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

Shots: Dr. Harmony gave the details about the positive 12-month findings from the P-IIIb SOLAR trial of the first and only complete long-acting injectable regimen Cabenuva vs. Biktarvy She also talked about the comparison of the Cabenuva regimen with the other existing & developing products for HIV including the Biktarvy regimen The interview gives an…
May 18, 2023

Read more

VIEWPOINTS_Gina Fusaro_2023
VIEWPOINTS

Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation on MAA for Opdivo

Shots: Gina gave her views on the acceptance of the sBLA by the US FDA and the validation of the Type II Variation Marketing Authorization Application by the EMA for Opdivo as monotherapy for the treatment of patients with completely resected stage IIB or IIC melanoma She also spoke on the epidemiology of melanoma and…
May 16, 2023

Read more

Load more